Source of funding and outcome of clinical trials

J Gen Intern Med. May-Jun 1986;1(3):155-8. doi: 10.1007/BF02602327.

Abstract

Because of recent concerns about conflicts of interest and published research, the author analyzed 107 controlled clinical trials. Studies were classified as favoring either a new therapy or a traditional therapy, and as being supported by a pharmaceutical manufacturer or as being generally supported. Seventy-one per cent of the trials favored new therapies; 43% of these were funded by pharmaceutical firms. Of the 31 trials favoring traditional therapy, only four (13%) were supported by a pharmaceutical firm. There was a statistically significant association between the source of funding and the outcome of the study (p = 0.002). Few trials supported by pharmaceutical manufacturers favored traditional therapy; some reasons for this finding may include selection of drugs likely to be proven efficacious, Type II errors (false-negative studies), and fear of discontinuation of funding should such studies be submitted. Important clinical information may be lost if negative studies are not published.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Biomedical Research*
  • Clinical Trials as Topic / economics*
  • Drug Industry / economics*
  • Editorial Policies
  • Research Support as Topic*